Natural Capsules Past Earnings Performance
Past criteria checks 2/6
Natural Capsules has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 21.8% per year. Natural Capsules's return on equity is 0.8%, and it has net margins of 1.3%.
Key information
18.2%
Earnings growth rate
11.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 21.8% |
| Return on equity | 0.8% |
| Net Margin | 1.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Natural Capsules makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,606 | 22 | 138 | 0 |
| 30 Jun 24 | 1,569 | 43 | 134 | 0 |
| 31 Mar 24 | 1,554 | 56 | 129 | 0 |
| 31 Dec 23 | 1,528 | 72 | 120 | 0 |
| 30 Sep 23 | 1,583 | 113 | 117 | 0 |
| 30 Jun 23 | 1,659 | 151 | 115 | 0 |
| 31 Mar 23 | 1,724 | 184 | 112 | 0 |
| 31 Dec 22 | 1,763 | 209 | 110 | 0 |
| 30 Sep 22 | 1,684 | 197 | 108 | 0 |
| 30 Jun 22 | 1,536 | 170 | 99 | 0 |
| 31 Mar 22 | 1,351 | 139 | 101 | 0 |
| 31 Dec 21 | 1,166 | 104 | 99 | 0 |
| 30 Sep 21 | 1,008 | 79 | 94 | 0 |
| 30 Jun 21 | 892 | 65 | 89 | 0 |
| 31 Mar 21 | 795 | 69 | 83 | 0 |
| 31 Dec 20 | 720 | 54 | 79 | 0 |
| 30 Sep 20 | 667 | 40 | 78 | 0 |
| 30 Jun 20 | 635 | 30 | 76 | 0 |
| 31 Mar 20 | 616 | 9 | 75 | 0 |
| 31 Dec 19 | 617 | 17 | 80 | 0 |
| 30 Sep 19 | 607 | 17 | 76 | 0 |
| 30 Jun 19 | 595 | 18 | 75 | 0 |
| 31 Mar 19 | 598 | 19 | 74 | 0 |
| 31 Dec 18 | 559 | 18 | 69 | 0 |
| 30 Sep 18 | 547 | 21 | 68 | 0 |
| 30 Jun 18 | 578 | 22 | 64 | 0 |
| 31 Mar 18 | 548 | 11 | 67 | 0 |
| 31 Dec 17 | 585 | 4 | 56 | 0 |
| 30 Sep 17 | 584 | 3 | 56 | 0 |
| 30 Jun 17 | 535 | 2 | 59 | 0 |
| 31 Mar 17 | 536 | 6 | 62 | 0 |
| 31 Dec 16 | 542 | 11 | 67 | 0 |
| 30 Sep 16 | 544 | 12 | 68 | 0 |
| 30 Jun 16 | 577 | 25 | 66 | 0 |
| 31 Mar 16 | 621 | 43 | 66 | 0 |
| 31 Dec 15 | 643 | 48 | 154 | 10 |
| 30 Sep 15 | 672 | 59 | 151 | 10 |
| 30 Jun 15 | 671 | 57 | 149 | 10 |
| 31 Mar 15 | 673 | 56 | 60 | 0 |
| 31 Dec 14 | 669 | 53 | 124 | 8 |
| 30 Sep 14 | 638 | 53 | 121 | 8 |
| 30 Jun 14 | 613 | 49 | 119 | 8 |
| 31 Mar 14 | 585 | 46 | 118 | 8 |
| 31 Dec 13 | 558 | 65 | 100 | 7 |
Quality Earnings: 524654 has high quality earnings.
Growing Profit Margin: 524654's current net profit margins (1.3%) are lower than last year (7.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524654's earnings have grown by 18.2% per year over the past 5 years.
Accelerating Growth: 524654's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524654 had negative earnings growth (-80.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: 524654's Return on Equity (0.8%) is considered low.